Related Experiment Video
Updated: Nov 21, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
HER2 in metastatic colorectal cancer: a new to target to remember
Lynn Bitar1, Joseph Zouein1, Fady Gh Haddad1
1Department of Hematology & Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Abstract:
Metastatic colorectal cancer is the second most common cause of cancer death. Standard chemotherapy in combination with targeted therapies represent the backbone for the treatment of advanced disease. However, options are limited for patients progressing on these regimens. Genetic testing can offer patients the opportunity to benefit from novel therapies, namely immune checkpoint inhibitors in microsatellite instability-positive tumors. HER2 overexpression has recently emerged as a potentially targetable tumor marker in colorectal cancer (CRC). Despite the absence of approvals for anti-HER2 therapies in CRC, many agents such as trastuzumab and pertuzumab were tested and demonstrated significant antitumor activity, even in heavily pretreated patients. Early trials are also evaluating lapatinib, T-DM1, tucatinib and other anti-HER2 agents in patients with metastatic CRC, with promising results.
Insights
Metastatic colorectal cancer treatment options are limited after standard therapies fail. Genetic testing and targeting HER2 overexpression with novel agents offer new hope for advanced colorectal cancer patients.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Metastatic colorectal cancer (CRC) is a leading cause of cancer mortality.
- Current treatments include chemotherapy and targeted therapies, but options for resistant disease are scarce.
- Genetic alterations, such as microsatellite instability and HER2 overexpression, are emerging as therapeutic targets in CRC.
Purpose of the Study:
- To review the current landscape of treatment for advanced colorectal cancer.
- To highlight the role of genetic testing in identifying patients who may benefit from novel therapies.
- To discuss the potential of targeting HER2 overexpression in metastatic CRC.
Main Methods:
- Review of current clinical practices and emerging therapeutic strategies for metastatic CRC.
- Analysis of data from clinical trials investigating targeted therapies, including immune checkpoint inhibitors and anti-HER2 agents.
- Exploration of the clinical significance of HER2 overexpression in colorectal cancer.
Main Results:
- Immune checkpoint inhibitors show promise in microsatellite instability-positive CRC tumors.
- Anti-HER2 therapies, including trastuzumab and pertuzumab, have demonstrated antitumor activity in pretreated metastatic CRC patients.
- Ongoing trials with agents like lapatinib, T-DM1, and tucatinib show encouraging results for HER2-positive CRC.
Conclusions:
- Genetic profiling is crucial for guiding treatment decisions in advanced colorectal cancer.
- Targeting HER2 offers a promising new avenue for patients with metastatic CRC, even those heavily pretreated.
- Further research and clinical trials are essential to establish the role of anti-HER2 therapies in CRC management.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle